Table 1. Baseline characteristics.
ECOG: Eastern Cooperative Oncology Group, IMDC: International Metastatic RCC Database Consortium
| Sunitinib (n:41) | Pazopanib (n:34) | p-value | |
| Age, median (range) | 59 (26-78) | 59 (28-74) | 0.912 |
| <65years | 21(51%) | 17(50%) | |
| ≥65years | 20(49%) | 17(50%) | |
| Sex | 0.825 | ||
| Male | 28 (68%) | 22 (65%) | |
| Female | 13 (32%) | 12 (35%) | |
| IMDC risk score at diagnosis | 0.835 | ||
| Favorable | 10 (24%) | 9 (26%) | |
| Intermediate-Poor | 31 (76%) | 25 (74%) | |
| Cytoreductive nephrectomy at diagnosis | 0.081 | ||
| No | 28 (68%) | 29 (85%) | |
| Yes | 13 (32%) | 5 (55%) | |
| ECOG performance status | 0.763 | ||
| 0-1 | 33 (80%) | 26 (77%) | |
| .2 | 8 (20%) | 8 (23%) | |
| Number of metastatic sites | 0.217 | ||
| Single | 19 (46%) | 11 (32%) | |
| Multiple | 22 (54%) | 23 (68%) | |
| Bone metastasis | 0.026 | ||
| Yes | 11 (27%) | 18 (53%) | |
| No | 30 (73%) | 16 (47%) | |
| Liver metastasis | 0.636 | ||
| Yes | 8 (20%) | 5 (15%) | |
| No | 33 (80%) | 29 (85%) | |
| Lung metastasis | 0.045 | ||
| Yes | 25 (61%) | 28 (82%) | |
| No | 16 (39%) | 6 (18%) | |
| Neutrophil lymphocyte ratio (median) | 2.9 | 3.2 | 0.549 |